Curevac does not pursue Covid vaccine further
The biotech wants to continue researching the method behind it, but withdraws its vaccine candidate.
The Tübingen-based biotech start-up Curevac is withdrawing its vaccine candidate from the race. The company announced on Tuesday that it will withdraw its vaccine CVnCov from the approval process at the European Medicines Agency (Ema). This is the grow-up's response to recent weak test results for its potential vaccine against the coronavirus.
The vaccine doses promised to the EU will thus no longer be delivered and contracts with Bayer, among others, will also become invalid. The chemical company was supposed to be responsible for the distribution of the vaccine.
Despite the setback, the start-up company, which has also received millions in funding from the German government , intends to continue its research with mRNA. However, together with GlaxoSmithKline, a large British pharmaceutical company, the company plans to work with so-called modified mRNA in future, just as Biontech, Pfizer and Moderna have done. The start-up company, which was founded in 2000, had previously specialised in unmodified mRNA.
Startups, stories and stats from the German startup ecosystem straight to your inbox. Subscribe with 2 clicks. Noice.LinkedIn Connect
Take care, give care
Did this news inform or entertain you? Then we would be happy if you tell your network about it.Share on Linkedin Share on Facebook Share on Xing
FYI: English edition available
Hello my friend, have you been stranded on the German edition of Startbase? At least your browser tells us, that you do not speak German - so maybe you would like to switch to the English edition instead?
FYI: Deutsche Edition verfügbar
Hallo mein Freund, du befindest dich auf der Englischen Edition der Startbase und laut deinem Browser sprichst du eigentlich auch Deutsch. Magst du die Sprache wechseln?